Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | PER2 | O15055 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL828845 | 0.84 | BRD4 (0.49) | BRD4CREBBPNPC1MAPK13MAPK12 | |
| SCHEMBL12087699 | 0.75 | BRD4 (0.49) | BRD4CREBBPNPC1MAPK13MAPK12 | |
| SCHEMBL22414473 | 0.74 | CRBN (0.35) | ALOX5 | |
| SCHEMBL2606232 | 0.73 | BRD4 (0.68) | BRD4CREBBPNPC1MAPK13MAPK12 | |
| SCHEMBL13068201 | 0.72 | BRD4 (0.43) | BRD4CREBBPNPC1MAPK13MAPK12 | |
| SCHEMBL13078127 | 0.71 | BRD4 (0.61) | BRD4CREBBPNPC1MAPK13MAPK12 | |
| SCHEMBL12253555 | 0.71 | BRD4 (0.44) | BRD4CREBBPNPC1MAPK13MAPK12 | |
| SCHEMBL13907678 | 0.69 | NPC1 (0.53) | BRD4CREBBPNPC1MAPK13MAPK12 | |
| SCHEMBL13311918 | 0.69 | ALDH1A1 (0.48) | MAPT | |
| SCHEMBL2603742 | 0.69 | BRD4 (0.49) | BRD4CREBBPNPC1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314117-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110251223-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251223-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | BRD4 2493/4885CREBBP 1534/4885NPC1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.